Shots:
- The company has stopped the P-II/III STAGED-PKD study for not meeting futility criteria that assess venglustat vs PBO in patients with ADPKD, following an independent analysis of the annualized rate of change in TKV
- The therapy did not bring a reduction in TKV growth rate and interim analysis showed the reduction of GSLs may not prevent kidney cyst growth and is not a primary pathway associated with the progression of ADPKD
- Biomarker data from the study confirmed that the therapy effectively inhibits the GSL pathway by a reduction in GL-1. The company is also evaluating the therapy for Gaucher disease type 3, Fabry disease, and GM2 Gangliosidosis
Click here to read full press release/ article | Ref: Globe Newswire | Image: CNN
The post Sanofi Stops the P-II/III STAGED-PKD Study of Venglustat for Autosomal Dominant Polycystic Kidney Disease first appeared on PharmaShots.
